3 US approvals within 12 months (Mcap 35 Mio$)

Replies to This Discussion

Permalink Reply by Carl Pechstein on March 9, 2010 at 3:01pm

A GREAT BUYING OPPORTUNITY AT THIS PRICE ....

CEO holds 6 Million Shares (35%)

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204...\2009\11\02\&CoName=INTELLIPHARMACEUTICS+INTERNATIONAL+INC.&FormType=SC+13D&RcvdDate=11%2F2%2F2009&pdf=


Great Management here..

Dr. Issa Odidi (CEO)

Dr. Issa Odidi is Founder, Chairman of the Board, Chief Executive Officer, Co-Chief Scientific Officer and Chair of the Scientific Advisory Board of IntelliPharmaCeutics. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.

Professor Issa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University in Nigeria, his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England.

Dr. Amina Odidi is a Founder, Director, President, Chief Operating Officer and Co-Chief Scientific Officer of IntelliPharmaCeutics.

Dr. Amina Odidi received her B.Sc. degree in Pharmacy, from Ahmadu Bello University, and her M.Sc., Biopharmaceutics and Ph.D Pharmaceutics degrees from the University of London, England.

The Chief Scientists at IntelliPharmaCeutics, Dr. Issa Odidi and Dr. Amina Odidi, are the inventors of each of the diverse core drug delivery technologies which the company now successfully exploits. They were also directly responsible for the design, development and advancement to production scale of each of the ten FDA-approved and commercially successful drugs and dosage strengths now on sale in the United States.

IntelliPharmaCeutics is a leading edge designer and developer of controlled release drug products. Backed by the Company's breakthrough HYPERMATRIX TM drug delivery technology, its world class team of R&D scientists have enjoyed unprecedented success in developing blockbuster controlled release drugs for their clients.

IntelliPharmaCeutics' track record in designing and developing controlled release drug products for its clients is second to none. Of the approximately 15 bio-equivalent controlled release products in the U.S. market today, 7 of them were designed and developed by the Company's scientists and now enjoy strong sales in the demanding U.S. market.

• ▶ Reply

Permalink Reply by Carl Pechstein on March 10, 2010 at 11:14am

Approval will push this stock over 5$ ...IPCI is a Lifetime opportunity at current level ..

• ▶ Reply

Permalink Reply by Carl Pechstein on March 11, 2010 at 11:39am

CORRECTION

Market Cap is 17 Mio$ NOT 35 Mio$

Shares Outstanding is 10,9 M not 22 M


http://files.shareholder.com/downloads/ABEA-43EQSZ/865020512x0x3544...

OUTSTANDING SHARE INFORMATION
The number of shares outstanding as of February 26, 2010, is 10.9 million and it has not changed since November 30, 2009. The number of options outstanding as of February 26, 2010, is 2,929,502 and has decreased since November 30, 2009 due to the expiry of 9,686stock options. No stock options were granted or forfeited since November 30, 2009.

• ▶ Reply

Permalink Reply by Carl Pechstein on March 12, 2010 at 11:14am

BIG News out for IPCI = MEANS US APPROVAL !!!!!

LOAD UP THE TRUCK WHILE ITS VERY VERY CHEAP !!

http://finance.yahoo.com/news/Intellipharmaceutics-pz-2496926109.ht...

Intellipharmaceutics Announces Settlement for its Generic Version of Focalin XR(R)

Press Release Source: Intellipharmaceutics International Inc. On Thursday March 11, 2010, 5:00 pm EST

TORONTO, March 11, 2010 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I - News) today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR(R) (dexmethylphenidate hydrochloride). The terms of the settlements are confidential and remain subject to regulatory and court approval.

• ▶ Reply

Permalink Reply by Carl Pechstein on March 12, 2010 at 1:19pm

LAST CHANCE TO BUY UNDER 2$ !!!!

MARKET CAP OF 19 MIO$ IS A BIG JOKE ..SEE YOU AT 10$+ SOON

• ▶ Reply

Permalink Reply by Carl Pechstein on March 12, 2010 at 1:36pm

RAALLLLYYYYYYYYYY.. STILL VERY VERY CHEAP
http://ih.advfn.com/p.php?pid=staticchart&s=N%5EIPCI&p=0&am...

• ▶ Reply

Permalink Reply by Carl Pechstein on March 12, 2010 at 2:29pm

Sp now at 4$ ( Market cap only 44 M$) ..IPCI is still wayyyyy undervalued .

• ▶ Reply

Permalink Reply by Erick A on March 12, 2010 at 3:34pm

Great call, but I missed it. Good luck to you

• ▶ Reply

Permalink Reply by Cole S on March 15, 2010 at 8:29am

Amazing call man

• ▶ Reply

Permalink Reply by Carl Pechstein on March 16, 2010 at 8:20am

Great Buying Opportunity at this price ....

The Long And Short Of Intellipharmaceutics International
http://www.rttnews.com/Content/CanadianNews.aspx?Node=B1&Id=123...


Market Watch for Intellipharmaceutics International Inc. Issued by Beacon Equity
http://finance.yahoo.com/news/Market-Watch-for-pz-4051491601.html?x...

• ▶ Reply

Permalink Reply by Carl Pechstein on March 19, 2010 at 9:20am

US approval is coming very soon ..Market cap of 29 Million$ is a joke . TIME TO BUY !!

TWST: Please begin with a brief history and overview of IntelliPharmaCeutics.

Dr. Odidi (CEO): IntelliPharmaCeutics International is a specialty pharmaceutical development company focused on difficult-to-formulate, controlled-release generic and branded drugs. I founded the predecessor company to IntelliPharmaCeutics International with my spouse, Dr. Amina Odidi, in 1998. Since our founding, we have expanded our premises twice and have put together an array of core assets, including seven proprietary drug delivery technologies, issued and pending patents, and a growing pipeline of Abbreviated New Drug Application (ANDA) and New drug Application (NDA) product candidates. We also have a successful history of establishing collaborative development and licensing arrangements with respected pharmaceutical companies. These arrangements are based on our drug development competence and well-earned trust. The focus of these relationships is directed to getting the best drug product to market in the shortest possible time. Our core technology is called Hypermatrix, a robust, validated, and proprietary technology platform that we have used to build a diverse pipeline of 15 generic and new drugs, with the underling brand sales of these targeted drugs being $15 billion. Our lead product, generic Focalin XR¨, is filed with the FDA and is partnered with Par pharmaceutical. We are also developing Rexistaª, a new drug product designed to overcome the well-documented abuses associated with oxycodone, a multibillion-dollar-selling compound. In October of last year, we completed a reverse takeover to become a publicly traded entity, and our shares began trading on the Nasdaq and Toronto Stock Exchanges.



TWST: You mentioned the drug delivery platform, the controlled-release drug delivery platform. How does that look?

Dr. Odidi(CEO): We believe that our Hypermatrixª technology is a revolutionary and robust controlled-release drug delivery platform. Hypermatrix is our core proprietary technology platform. It is a drug matrix technology defined as five dimensional in nature, encompassing length, height, width, space and time. Understanding and controlling of properties associated with these dimensions facilitates time-released delivery of a wide range of pharmaceuticals. Essentially this a very robust and flexible technology that allows us to delivery virtually any active pharmaceutical ingredient or drug to the body in the right amount, in the right place and at the right time.
The Hypermatrix platform works within the human body, responding to the multivariate external environment of the gastro-intestinal tract (GIT), releasing drug at the desired time and according to the desired profile. All this is achieved with spatial recognition and control of the optimum GIT site for drug release; defensive control over adverse factors, such as food effects or excess acidity; temporal control over the time when drug release commences or ends; structural control over the physical characteristics of the solid dosage form from ingestion to full release; rate control over the entire release profile to deliver true "intelligent" extended release.
We apply Hypermatrix together with our extensive expertise in pharmaceutics, drug delivery and drug manufacture with the goal of minimizing the risk, time and manufacturing cost of bringing high-value finished products to market. We use this technology to both develop our internal pipeline and to assist other pharmaceutical companies with product development.

• ▶ Reply

Permalink Reply by Carl Pechstein on March 19, 2010 at 1:24pm

IPCI is on the move again eom ....

• ▶ Reply

• ‹ Previous
• 1
• 2
• Next ›
• Page